---
document_datetime: 2025-10-22 10:00:26
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ultomiris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ultomiris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3017045
conversion_datetime: 2025-12-21 18:25:39.439802
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ultomiris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 11/09/2025                          |                                             | SmPC,                            | SmPC new text: Section 4.4 warning on polysorbate |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000271811                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.8 and 5.1 of the SmPC in order to update the summary of safety profile and efficacy information in adult patients with NMOSD based on final results from study ALXN1210-NMO-307; this is a Phase 3, External Placebo-Controlled, Open- Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). In addition, the MAH took the opportunity to introduce editorial, formatting and QRD-related changes to the PI, including an update to the excipient information. The list of local representatives in the Package Leaflet has also been   |            | Labelling and PL                 | 80 content is added Section 4.8 in the summary of safety profile frequencies of AEs are updated and meningococcal meningitis is added as preferred term under meningococcal infections. The following text is added under Section 5.1 Study in adult patients with NMOSD In the final efficacy analysis with median follow up of 170.29 weeks, no adjudicated on-trial relapses were observed in ravulizumab treated patients through the end of study. Ravulizumab treatment responses observed during the Primary Evaluation Period were maintained throughout the duration of the study. In addition, among the 27 patients on IST treatment at Baseline, 17 (63%) had a decrease or stopped at least one IST therapy during treatment with ravulizumab. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000279290 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/08/2025 | SmPC, Annex II, Labelling and PL | To withdraw EU/1/19/1371/001, Ultomiris 300 mg/30 mg (10 mg/ml) concentrate for solution for infusion (intravenous use).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                            | reagent or excipient (when mentioned in the dossier)* - Accepted B.I.d.1.b Storage conditions - B.I.d.1.b.3 Change in storage conditions of the active substance - Accepted C.I.7 Deletion of: - C.I.7.b a strength - Accepted   |             |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| PSUR / EMA/PSUR/0000257874 | - -                                                                                                                                                                                                                              | Maintenance |